CONTEC was established in 1992 and is a high-tech enterprise specializing in the R&D, production, and sales of medical diagnostic and monitoring equipment. CONTEC products cover a wide range including oximeters, electrocardiographs, ultrasound devices, monitors, blood pressure and respiratory equipment, and have been sold to over 140 countries and regions globally. On August 24th, 2020, CONTEC was listed on the Shenzhen Stock Exchange, with the stock code: 300869.
Compulink Healthcare Solutions
Compulink, a 40-year leader in Digital Health, empowers practices to boost efficiency and profitability with AI-powered orthopaedic EHR and Practice Management solutions. Our customizable all-in-one suite includes patient engagement, ASC software, PACS integration, analytics, inventory management, and revenue cycle management. | Compulink, a 40-year leader in eye care, empowers practices to boost efficiency and profitability with AI-powered ophthalmology EHR and Practice Management solutions. Our customizable all-in-one suite includes patient engagement, ASC software, Optical point of sale, analytics, 140+ equipment interfaces, RCM, eCommerce and marketing services.
Complete Genomics
Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions, including sample/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers, ranging from low to high throughput capacities, all powered by its proprietary DNBSEQ technology. Over 10,900 publications have been based on DNBSEQ technology across a wide range of applications. Complete Genomics is the exclusive distributor for STOmics products, powered by Stereo-seq technology —the only spatial technology globally capable of accessing the whole transcriptome at true single-cell resolution. | Complete Genomics is a pioneering life sciences company offering innovative, comprehensive sequencing solutions, including sample/library preparation, lab automation, sequencing, and data analysis. Our sequencing portfolio features a full range of sequencers designed to meet low, medium, and high throughput needs, all powered by our proprietary DNBSEQ technology. To date, over 9,700 publications have utilized DNBSEQ technology across a broad spectrum of applications. As the exclusive distributor of STOmics products in North America, Complete Genomics provides access to Stereo-seq technology—the only spatial transcriptomics solution worldwide capable of exploring the entire transcriptome at true single-cell resolution. To learn more, visit https://www.completegenomics.com
Coherence Biotech Co. Ltd.
Coherence Bio is a lab automation company developing tools to accelerate AI based drug discovery, through end-to-end automation of cell-based testing.
Codonics
Codonics is an award-winning, USA-made leader in medical imaging devices, delivering premium and value-based solutions to meet every need and budget. • DICOM Printing Solutions: Produce diagnostic film and grayscale paper, ideal for patient consultations and referrals. • Disc Publishers: Efficiently record large studies and reports onto CD/DVD/USB directly from the modality, ready for patients to take home. • DR Retrofit Solutions: Transform analog rooms into state-of-the-art DR suites with our bundled solutions, including a Codonics imager—an attractive, all-in-one package. • Portable X-Ray Bundles: Designed for any setting, from ICUs to field hospitals and NGOs. Capture high-resolution digital chest x-rays in seconds with seamless DR integration and immediate film output with the included Horizon Imager for fast diagnosis and archiving. • NEW! Radiology Image Share Smart Solutions: Digitization and secure sharing of medical imaging data, including DICOM burning, archiving, printing and sharing. With over 65,000 installations in 110 countries, Codonics is trusted worldwide for outstanding quality, innovation, and a lower total cost of ownership. Visit us to explore our latest breakthroughs and discover how we can help grow your business.
COD Research USA Inc
COD Research is a leading CRO based in the US and India, specializing in global clinical trials and pharmacovigilance services. With a strong focus on biosimilar trials worldwide, we offer tailored solutions, ensuring quality, compliance, and client satisfaction. Our commitment is to contribute to the advancement of healthcare by delivering reliable and efficient services on an international scale. | We are a technical full-service Contract Research Organization (CRO) that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly integrate with your teams, whether you require functional services for global studies or tailored on-site and off-site support. | We are a technical Full Service CRO that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly adapt to client requirements, whether you require functional solutions or global studies or tailored on-site and off-site support.
CNCure Co., Ltd.
CNCure is a pioneering biotech startup dedicated to revolutionizing cancer therapy and diagnostics. We specialize in developing bacteria-based cancer immunotherapeutics and theranostic platforms leveraging microbial theapeutics and nuclear medicine. One of our core technologies is the Salmonella-based Armed Microbe (SAM) platform, which utilizes innovative approaches to target tumors and enhance anticancer immune responses. Our flagship products, CNC-101 and CNC-105, directly target tumors, induce immune responses, and establish long-term antitumor immunological memory to prevent recurrence. In addition, CNCure is advancing diagnostic technologies with radiotracer-based tools for the high-sensitivity detection of fatal diseases such as fungal infections. Our [18F]FDS and [18F]DMPY2 tracers enable high-resolution visualization of gram-negative bacterial and fungal infections and malignant melanoma, respectively. CNCure is dedicated to pioneering innovations in cancer treatment, striving to improve patient outcomes and quality of life on a global scale. By actively participating in numerous national and international R&D projects, we continue to drive groundbreaking research and development. Our extensive patent portfolio is a testament to our technological excellence and commitment to shaping the future of oncology. Founded in 2019 by leading experts in cancer immunotherapy and radiopharmaceuticals, CNCure has developed a robust scientific foundation, a cutting-edge technology platform, and a strong pipeline. In the second half of 2024, we were honored to be one of only 14 companies, out of over 100 applicants, selected for Johnson & Johnson’s JLABS Korea program, which aims to accelerate life-science innovation. As we advance the clinical development and commercialization of our theranostic candidates, we actively seek joint-development partnerships and investments to expand our global presence. Our vision is to revolutionize cancer treatment through groundbreaking bacteria-based immunotherapies and radiopharmaceuticals that address critical unmet medical needs. | CNCure Co., Ltd. is a pioneering biotechnology company based in Hwasun, Republic of Korea, dedicated to revolutionizing cancer therapy and diagnostics. Founded in 2019, CNCure specializes in bacteria‑based cancer immunotherapeutics and integrated theranostic platforms leveraging microbial and nuclear medicine. The company’s lead candidate, CNC‑101, is a next‑generation bacterial immunotherapy built on attenuated Salmonella typhimurium technology, designed to selectively colonize the tumor microenvironment and reprogram it into an immuno‑active state that enhances anti‑tumor immune responses. Preclinical data demonstrate promising efficacy and safety profiles across multiple solid tumor models. Beyond immuno‑oncology, CNCure is advancing radiopharmaceutical and theranostic platforms that combine imaging and therapy for improved tumor targeting, treatment monitoring, and personalized decision‑making. CNCure actively pursues global partnerships and business development to translate its innovative platforms into clinical applications that address unmet medical needs. CNCure continues to present its scientific and clinical progress at major international conferences.